What is Immuneering?
Immuneering is dedicated to pioneering universal-RAS/RAF medicines for a broad spectrum of cancer patients. By employing a strategy of Deep Cyclic Inhibition of the MAPK pathway, the company aims to effectively target cancer cells while minimizing harm to healthy tissues. Its lead product candidates, IMM-1-104 and IMM-6-415, are both oral Deep Cyclic Inhibitors currently undergoing Phase 1/2a trials for advanced solid tumors with RAS or RAF mutations, respectively. The company's pipeline also features several early-stage programs, positioning it at the forefront of precision oncology.
How much funding has Immuneering raised?
Immuneering has raised a total of $219.5M across 4 funding rounds:
Series A
$20M
Series B
$62M
Share Placement
$112.5M
Private Equity
$25M
Series A (2020): $20M with participation from Boxcar PMJ LLC
Series B (2021): $62M led by BlackRock, Rock Springs Capital, Perceptive Advisors, Cormorant Asset Management, T. Rowe Price, LYFE Capital, and Surveyor Capital
Share Placement (2021): $112.5M, investors not publicly disclosed
Private Equity (2025): $25M, investors not publicly disclosed
Key Investors in Immuneering
BlackRock
BlackRock is a global investment management firm offering a wide array of investment products and services, including mutual funds and ETFs, to institutional and individual investors worldwide. They manage assets across various classes using diverse investment strategies.
Rock Springs Capital
Rockspring Capital is a real estate investment firm with extensive experience in the Texas market, specializing in various asset classes including residential, retail, and industrial development. They provide local expertise to investors.
Perceptive Advisors
Perceptive Advisors is an investment firm focused on funding innovative healthcare and life sciences technologies, managing significant assets dedicated to advancing medical breakthroughs.
What's next for Immuneering?
The substantial enterprise-level backing and recent strategic investment signal a critical growth phase for Immuneering. This financing is poised to fuel the progression of its clinical trials, potentially leading to regulatory submissions and commercialization. The company's focus on a well-defined mechanism of action and a clear development pathway suggests a strategic intent to address significant unmet needs in oncology. Future developments will likely center on demonstrating clinical efficacy and safety, attracting further investment, and forging strategic partnerships to expand market reach.
See full Immuneering company page
